SCHEMBL5651961

SCHEMBL5651961

COc1cc2nncc(-n3ncc4cc(-c5cccnc5)ccc43)c2cc1OC

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 7/20 0.56
PDGFRB P09619 1/20 0.47
PDGFRA P16234 1/20 0.47
CYP11B2 P19099 5/20 0.45
CYP11B1 P15538 4/20 0.45
CYP19A1 P11511 3/20 0.45
PDPK1 O15530 2/20 0.43
CYP17A1 P05093 2/20 0.43
ATM Q13315 1/20 0.41
KDM4E B2RXH2 1/20 0.39
MAPK1 P28482 1/20 0.39
HSD17B10 Q99714 1/20 0.39
MKNK1 Q9BUB5 1/20 0.39
MKNK2 Q9HBH9 1/20 0.39
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
PDE4A P27815 1/20 0.38
PDE4B Q07343 1/20 0.38
PDE3B Q13370 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4982681 0.89 PDGFRB (0.44) PDE10APDGFRBPDGFRAATM
SCHEMBL4778162 0.81 FLT1 (0.41) PDE10APDGFRBPDGFRAPDPK1
SCHEMBL5653371 0.81 PDE10A (0.47) PDE10APDGFRBPDPK1KDM4EHSD17B10
SCHEMBL5653771 0.75 KDR (0.41) PDE10APDGFRBPDPK1
SCHEMBL4977487 0.74 PDGFRB (0.50) PDE10APDGFRBPDGFRAPDPK1NPC1
SCHEMBL4987899 0.73 PDE10A (0.47) PDE10APDGFRBPDGFRACYP17A1
SCHEMBL4977732 0.73 IRAK4 (0.42) PDE10APDGFRB
SCHEMBL5652893 0.73 PDE10A (0.49) PDE10APDGFRBKDM4EHSD17B10SMN1; SMN2
SCHEMBL5245875 0.73 PDE10A (1.00) PDE10APDGFRBPDGFRAPDE4APDE4B
SCHEMBL4778828 0.71 PDE10A (0.43) PDE10APDGFRBKDM4ENPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070265270-A1 Cinnoline derivatives as phosphodiesterase 10 inhibitors MEMORY PHARMACEUTICALS CORPORATION 2007-11-15 US disclosed
US-20070265270-A1 Cinnoline derivatives as phosphodiesterase 10 inhibitors MEMORY PHARMACEUTICALS CORPORATION 2007-11-15 US disclosed
US-20070265270-A1 Cinnoline derivatives as phosphodiesterase 10 inhibitors MEMORY PHARMACEUTICALS CORPORATION 2007-11-15 US disclosed
WO-2007098214-A1 CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS AMGEN INC. (US) 2007-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265270-A1 Cinnoline derivatives as phosphodiesterase 10 inhibitors PDE7A, PDE10A, PDE7B PDE10A 2/4885PDGFRB 3311/4885PDGFRA 3496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.